Besides, combination of GP IIb/IIIa inhibitors was a risk factor for AEs, ADRs and thrombocytopenia, which indicated that GP IIb/IIIa inhibitors might be carefully used in STEMI patients undergoing PCI and receiving bivalirudin as anticoagulant. The gene discussed is ITGA2B; the disease is Thrombocytopenia.